CSL Behring...FDA approved factor IX with albumin (rIX-FP)

Behring重组融合蛋白获得FDA颁发罕见药身份 发布时间：2012/6/12 13:31:00 来源：药品资讯网信息中心CSL Behring公司用于连接凝结因子IX和融合蛋白的重组融合蛋白，获得美国食品药监局(FDA)授予的罕见药身份。这种药用于治疗和预防先天IX因子不足患者(血友病)的出血。CSL Berhring公司研发高级副总裁Val Romberg说：“此次获得认证，是对公司在重组因子研发领域努力的一个认可。”它的长生理的半衰期,良好的耐受性方面更好、低免疫原性反应和潜力的一个众所周知的机制间隙比其他技术、白蛋白被选为重组基因融合凝血因子蛋白的合作伙伴。可裂解接头能够将重组因子IX和重组蛋白连接到一起，为的是在融合蛋白保护凝固因子的固有功能。

CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The Orphan Drug Designation is granted for the treatment and prophylaxis of bleeding episodes in patients with congenital factor IX deficiency (hemophilia B). The designation includes routine prophylaxis treatment, control and prevention of bleeding episodes, and prevention and control of bleeding in perioperative settings. CSL Behring is developing this therapy in collaboration with its parent company CSL Limited (ASX: CSL)."CSL Behring is pleased to have achieved this important regulatory milestone for our recombinant factor IX," said Val Romberg, Senior Vice President, Research and Development at CSL Behring. "It represents yet another advance that our company is making in the area of recombinant factor development and is extremely encouraging."CSL Behring has engineered rIX-FP to extend the half-life of Factor IX through genetic fusion with recombinant albumin. Albumin has been chosen as the ideal recombinant genetic fusion partner for coagulation factor proteins due to its long physiological half-life. In addition, albumin has been shown to have a good tolerability profile, low potential for immunogenic reactions and a well-known mechanism of clearance compared to some other technologies. The cleavable linker connecting recombinant factor IX and recombinant albumin has been specifically designed to preserve the native function of the coagulation factor in the fusion protein, while benefiting from recombinant albumin's long physiological half-life.The FDA's Orphan Drug Designation program provides orphan status to unique drugs and biologics, defined as those intended for the safe and effective treatment or prevention of rare diseases that affect fewer than 200,000 people in the U.S.